ABSTRACT
Twenty-four male patients who underwent left ventricular assist device (LVAD) implantation due to advanced heart failure in Union Hospital, Fujian Medical University from June 2019 to June 2022 were retrospectively included. The age of patients was 32-61 (48.4±8.4) years. Everheat-â , HeartCon and Corheart 6 left ventricular assist systems were used in 10, 6 and 8 cases, respectively. All patients were discharged successfully without mechanical failure, thrombosis or secondary thoracotomy for hemostasis. Early postoperative hemodynamics were significantly improved, left ventricular systolic diameter was reduced, left ventricular ejection fraction was gradually improved, and no hemolysis occurred. The patients were followed up for 3 to 39 (17.9±8.6) months, the cardiac function was restored to grade â to â ¡, and the 6-minute walking test distance increased significantly. Therefore, satisfactory early results can be achieved with left ventricular assist device implantation for the treatment of heart failure.
Subject(s)
Heart Failure , Heart-Assist Devices , Humans , Male , Adult , Middle Aged , Stroke Volume , Retrospective Studies , Ventricular Function, Left , Treatment Outcome , Heart Failure/surgeryABSTRACT
We have recently cloned the human fms-like tyrosine kinase 4 gene FLT4, whose protein product is related to two vascular endothelial growth factor receptors FLT1 and KDR/FLK1. Here the expression of FLT4 has been analyzed by in situ hybridization during mouse embryogenesis and in adult human tissues. The FLT4 mRNA signals first became detectable in the angioblasts of head mesenchyme, the cardinal vein, and extraembryonally in the allantois of 8.5-day postcoitus (p.c.) embryos. In 12.5-day p.c. embryos, the FLT4 signal decorated developing venous and presumptive lymphatic endothelia, but arterial endothelia were negative. During later stages of development, FLT4 mRNA became restricted to vascular plexuses devoid of red cells, representing developing lymphatic vessels. Only the lymphatic endothelia and some high endothelial venules expressed FLT4 mRNA in adult human tissues. Increased expression occurred in lymphatic sinuses in metastatic lymph nodes and in lymphangioma. Our results suggest that FLT4 is a marker for lymphatic vessels and some high endothelial venules in human adult tissues. They also support the theory on the venous origin of lymphatic vessels.
Subject(s)
Endothelium, Lymphatic/embryology , Receptor Protein-Tyrosine Kinases/biosynthesis , Receptors, Cell Surface/biosynthesis , Adenocarcinoma/genetics , Adenocarcinoma/secondary , Animals , Cells, Cultured , Endothelium, Lymphatic/cytology , Endothelium, Lymphatic/enzymology , Humans , In Situ Hybridization , Lymph Nodes/chemistry , Lymph Nodes/pathology , Lymphangioma/genetics , Mice , RNA, Messenger/isolation & purification , Receptor Protein-Tyrosine Kinases/genetics , Receptors, Cell Surface/genetics , Receptors, TIE , Tissue Distribution , Vascular Endothelial Growth Factor Receptor-3ABSTRACT
The chloroperoxidase gene from the filamentous fungus Caldariomyces fumago has been isolated within a 16.3-kilobase insert in the vector lambda EMBL3. The DNA sequence of the gene and its immediate flanking regions has been determined, and the start site of transcription has been mapped by primer extension.
Subject(s)
Chloride Peroxidase/genetics , Genes, Fungal , Mitosporic Fungi/genetics , Peroxidases/genetics , Base Sequence , Chloride Peroxidase/biosynthesis , Cloning, Molecular , DNA Restriction Enzymes , DNA, Fungal/genetics , Gene Expression Regulation , Mitosporic Fungi/enzymology , Molecular Sequence Data , Nucleic Acid Hybridization , Protein Biosynthesis , Software , Transcription, GeneticABSTRACT
The secreted form of the halogenating glycoenzyme, chloroperoxidase, is processed from a precursor containing a 21-residue-long, moderately hydrophobic signal sequence, at an atypical Gln-Glu peptide bond. Following cleavage, the N-terminal glutamic acid readily cyclizes into pyroglutamic acid. Chloroperoxidase contains two high-mannose N-glycosylation sites, identified as Asn12 and Asn213. Other modifications include deamidation of residues Asn13, Asn198, and Gln183 into the corresponding acids. Finally, structural arguments suggest that Cys87 may be the axial heme ligand in the active site of chloroperoxidase.
Subject(s)
Chloride Peroxidase/metabolism , Isoenzymes/metabolism , Mitosporic Fungi/enzymology , Peroxidases/metabolism , Protein Processing, Post-Translational , Amino Acid Sequence , Amino Acids/metabolism , Asparagine/metabolism , Chloride Peroxidase/isolation & purification , Chromatography, High Pressure Liquid , Glutamates/metabolism , Glutamic Acid , Glutamine/metabolism , Glycosylation , Isoenzymes/isolation & purification , Peptide Fragments , Protein Conformation , Protein Sorting SignalsABSTRACT
An oligod-d(T) 12-18 primed cDNA library has been prepared from Caldariomyces fumago mRNA. A clone containing a full-length insert was sequenced on the supercoiled plasmid, pBR322. The complete primary sequence of chloroperoxidase has been derived. We have also determined about 73% of the peptide sequence by amino acid sequencing. The DNA sequence data matches all of the available known peptide sequences. The mature polypeptide contains 300 amino acids having a combined molecular weight of 32,974 daltons. A putative signal peptide of 21 amino acids is proposed from DNA sequence data. The chloroperoxidase gene encodes three potential glycosylation sites recognized as Asn-X-Thr/Ser sequences. Three cysteine residues are found in the protein sequence. A small region around Cys87 bears a minimal homology to the active site of cytochrome P450cam. No other heme protein homologues can be detected. We propose that Cys87 serves as a thiolate ligand to the iron of heme prosthetic group. A rare arginine codon, AGG, is used three times out of twelve in contrast to the very infrequent use of this codon in E. coli or yeast.
